nnc9204-1177
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2016 (NCT02941042)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glucagon receptorAGONIST
GCGR agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nnc9204-1177
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04059367 | Phase 1 | Aug 20, 2019 | Novo Nordisk |
| NCT03308721 | Phase 1 | Oct 16, 2017 | Novo Nordisk |
| NCT02941042 | Phase 1 | Oct 10, 2016 | Novo Nordisk |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 3 | 3 | 1 | 2016 |
1 organizations
Page 1 / 1